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Objective: This study aimed to investigate whether interleukin-28A (IL-28A) plays a role in
murine  myocarditis induced by coxsackievirus B3 (CVB3), and to explore its possible mech-
anism  involved.
Methods: Male BALB/c mice both infected and not infected by CVB3 were randomly divided
into  four groups (n = 40), untreated or treated with different doses of IL-28A for 4 days,
and  then sacriﬁced on days 4 and 7 post-infection. The heart samples were collected for
histopathologic  examination. Cardiac viral load was determined by a plaque assay. Addi-
tionally,  immunoblot analysis, TUNEL assay, and immunohistochemistry were  performed
to  examine the expression of signal transducer, activator of transcription 1 and 2 (STAT1
and  STAT2), CVB3-induced apoptosis and the expression of Bcl-2, BAX and Caspase-3.
Results: Compared to uninfected mice, the CVB3 infected mice exhibited higher mortality
rate  (p < 0.001), apparent inﬂammation and myocardial lesion (p < 0.01), and higher car-
diac  viral load (p < 0.01). After CVB3 infection, IL-28A treated mice presented no death
(p  < 0.001), reduced inﬂammation and myocardial lesion (p < 0.01), and lower viral load
(p  < 0.01) compared to untreated mice. Besides, treatment with IL-28A markedly increased
the  expressions of STAT1 and STAT2, and inhibited CVB3-induced apoptosis in myocardial
cells  with increased ratio of Bcl-2/BAX.
RA
CT
EDConclusion: The antiviral and myocyte protective effects of IL-28A in CVB3-induced
myocarditis are regulated by STAT1 and STAT2.
©  2014 Published by Elsevier Editora Ltda.
However, coxsackievirus B3 (CVB3) is considered the most
ET
IntroductionR
Myocarditis is a cardiac disease associated with inﬂammation
and  injury of the myocardium. Several types of viruses have
∗ Corresponding author at: Department of Cardiology, Renmin Hospital o
District, Wuhan, Hubei, 430060, PR China.
E-mail address: huangfornew@163.com (C. Huang).
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1413-8670/© 2014 Published by Elsevier Editora Ltda.been implicated in the development of human myocarditis.1f Wuhan University, Wuhan University, 238 Jiefang Road, Wuchang
common  pathogen. CVB3-induced myocarditis is frequently
complicated by cardiomyopathy, left ventricular dysfunction,
and  chronic heart failure.2 The murine model of CVB3-induced
 2 0 1 
m
D
C
C
a
v
h
c
h
t
a
c
t
c
m
a
(
I
a
t
(
(
(
h
v
a
s
t
i
i
s
S
h
o
M
M
T
e
A
D
B
f
C
e
i
d
u
e
g
g
m
4
N
f
Ab r a z j i n f e c t d i s .
yocarditis shares many  features with human disease.3
espite decades of extensive efforts, the pathogenesis of
VB3-induced myocarditis is still not well deﬁned. Although
VB3  causes cellular dysfunction either through induced cell
poptosis,  shut down  of cell RNA and protein synthesis or
iral  protease cleavage of contractile proteins,4–7 the strong
ost  Th1 immune responses maybe more  responsible for the
ourse  of myocyte damage, veriﬁed by the improvement of
eart  injury and function by immune modulating and inhibi-
ing  agents.8–10 Clinical studies have also found cytokines such
s  IL-1, IL-6 and TNF- that were  involved in the course of
ardiac  dysfunction.11 Besides, the poor prognosis for more
han  half of patients presenting with clinical symptoms, since
urrently  no effective therapy is available for this disease,12,13
uch  work on the development of vaccines and therapeutic
gents against CVB3 has been done.
Human IL-28A, IL-28B, and IL-29, also known as interferon
IFN)-2, -3 and -1, respectively, belonging to the type III
FNs.14 Like other typical IFNs, these cytokines have been
lso  demonstrated to play a key role in the negative regula-
ion  of cytopathic viruses such as encephalomyocarditis virus
EMCV),15 vesicular stomatitis virus (VSV),15 cytomegalovirus
CMV),16 inﬂuenza A virus (IAV),17 respiratory syncytial virus
RSV),  hepatitis B virus (HBV),18 hepatitis C virus (HCV),18 and
erpes  simplex virus-2 (HSV-2).19 A growing number of pre-
ious  reports have suggested that type III IFNs exert antiviral
ctivity  by the induced upregulation of IFN effector proteins
uch  as STAT proteins.14,20 However, a recent study has shown
hat  certain types of viruses can develop mechanisms to
nhibit  the antiviral activity of type III IFNs.21
This study aimed to investigate whether IL-28A plays a role
n  murine myocarditis induced by CVB3, and to explore its pos-
ible mechanism involved by determining the expressions of
TAT1  and STAT2, Bcl-2, BAX, and Caspase-3 in CVB3-infected
eart  tissues. It will provide a reference for the development
f  vaccines and therapeutic agents against CVB3 in human.
aterials  and  methods
ice,  CVB3  infection,  and  IL-28A  treatment
he research protocol of this study was  approved by the
thical  Committee of Wuhan University School of Medicine.
nimal  handling was  carried out according to the Wuhan
irective for Animal Research. A total of 240 healthy male
ALB/c  mice (4-week old), weighing 10–12 g, were  purchased
rom  the Animal Center of Hubei Province (Wuhan, Hubei,
hina)  and had free access to food and water during the
xperiments. Among them, 160 randomly selected mice were
noculated  intraperitoneally with CVB3 (Nancy strain) at a
ose  of 105 plaque-forming units (pfu) in a volume of 100 L
sing  phosphate buffered saline (PBS) as a vehicle, and divided
venly  into 4 groups (n = 40), including infected but untreated
roup,  low-dose, mild-dose and high-dose IL-28A treated
roups.  Starting 1 h after infection, these CVB3 inoculated
RE
TRice received intraperitoneal injection with PBS, 10, 20, or
0  g/kg of recombinant murine IL-28A (Peprotech, Rocky Hill,
J),  respectively, followed by daily subcutaneous injection
or  4 days. The 80 uninfected mice, divided evenly into two5;1 9(2):132–140  133
groups  that were either intraperitoneally inoculated with PBS
(n = 40, control group) or 40 g/kg IL recombinant murine IL-
28A  (n = 40, IL-28A group). Ten mice from each group were
euthanized on days 4 and 7 post-infection, respectively. The
hearts  were exposed, perfused with 5 mL  PBS through the left
ventricle,  and then isolated. Approximately 10 mg  of tissues
from  cardiac apex were excised and weighed for plaque assay,
whereas  the remainder of the heart was  ﬁxed in 10% neutral
formalin for histopathologic examination as described below.
The  remaining 20 mice of each group were  monitored for
health  status and survival analysis.
Histopathology
The hearts were ﬁxed in 10% neutral formalin for 24 h, embed-
ded  in parafﬁn, and then cut into 4 m-thick sections (about
four  sections per heart). Then the sections were  stained with
hematoxylin and eosin (H&E) and used to assess inﬂamma-
tory  inﬁltration, myocardial lesion or necrosis. The extent of
inﬂammation  and generalized myocardial ﬁber necrosis were
blindly scored by a pathologist based on the following scale:
0,  absent; 0.5, rare; 1.0, 10% of myocardial area affected; 2.0,
25%  area affected; 3.0, 25–50% area affected; 4.0, >50% area
affected.  The two scores reﬂecting the extent of inﬂammation
and  myocardial lesion were then averaged to yield an inte-
grated  pathology (IP) score as an indicator of overall injury.22
Viral  plaque  assays
The viral plaque assay was  performed as previously described
to  determine cardiac viral load.22 One piece of heart apex
(10  mg)  was removed aseptically, weighed, and stored at
−80 ◦C. Then the frozen heart tissue was homogenized in
200  L PBS and centrifuged at 12,000 rpm for 5 min. Viral titer,
expressed  as pfu/mL, was determined from the supernatant
of  the heart homogenate by a plaque assay on HeLa cell mono-
layers  according to previous study.23
Western  blot  analysis
Western blot analysis was  performed as described in
the  literature to evaluate the expressions of STAT1 and
STAT2.24 The ventricles of mice were homogenized in a
lysis  buffer consisting of 10 mM HEPES, pH 7.4, 150 mM
NaCl,  5 mM EDTA, 1 mM sodium-orthovanadate, 20 M 4-
(2-aminoethyl)-benzenesulfonyl ﬂuoride, 0.2% Nonidet P-40,
5  g/mL leupeptin, and protease inhibitor cocktail (Sigma, St.
Louis,  MO). The homogenates were centrifuged at 12,000 rpm
for  10 min  at 4 ◦C, and supernatants were collected to deter-
mine  the protein concentrations using the DC protein assay
(Bio-Rad,  Hercules, CA). The equal amounts of protein (40 g)
from  each sample were  separated by sodium dodecyl–poly
acrylamie gel electrophoresis (SDS-PAGE) using 4–12% NuPAGE
Novex  precast Bis-Tris gradient gels (Invitrogen, Carlsbad, CA)
and transferred onto polyvinylidene diﬂuoride (PVDF) mem-
branes  (Bio-Rad, Hercules, CA). The membranes were  blocked
CT
EDin  5% BSA for 40 min  at room temperature and then incu-
bated  individually at 4 ◦C overnight with primary antibodies,
including rabbit polyclonal antibodies against STAT1 (1:1000)
and  actin (1:2000), and mouse monoclonal antibodies against
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Fig. 1 – IL-28A prevented mice with CVB3-induced
myocarditis from dying. The survival rate was  analyzed by
the Kaplan–Meier estimate. The IL-28A treated mice had
higher  survival rates than the untreated infected group
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STAT2 (1:200) (Cell Signaling Technology, Inc., Danvers, MA).
After  three washings with TBST, membranes were incubated
at  room temperature for 40 min  with the secondary antibodies
including horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (1:10,000) and goat anti-mouse IgG (1:5000) (Santa
Cruz  Biotechnology, Inc., Dallas, TX). The signals from the
bound  antibodies were  detected using the SuperSignal West
Pico  Chemiluminescent Substrate Kit (Pierce, Rockford, IL).
Immunohistochemistry
Immunohistochemistry was  performed to assess the expres-
sions  of Bcl-2, BAX and Caspase-3 according to the instructions
of  the manufacturer. Brieﬂy, parafﬁn-embedded myocardial
sections were deparafﬁnized in xylene and rehydrated in a
series  of graded concentrations of ethanol. Protein antigenic-
ity  was  enhanced by boiling the sections in a citrate buffer
with  microwave for 15 min. Endogenous peroxidase activity
was  blocked with 3% hydrogen peroxide in PBS for 20 min  at
37 ◦C. Then the sections were washed with distilled water, and
incubated  with the primary antibodies against BAX (1:100),
Bcl-2  (1:100), and caspase-3 (1:100) (Santa Cruz Biotechnol-
ogy,  Inc., Dallas, TX) at 4 ◦C overnight, followed by staining
with  a streptavidin–biotin–peroxidase kit (Beijing Zhongshan
Biotechnology Co., Ltd, Beijing, China). The immunoreactions
were  then visualized with a 3,3-diaminobenzidine solution
(Beijing  Zhongshan Biotechnology Co., Ltd, Beijing, China),
counterstained with hematoxylin, and mounted. For nega-
tive  controls, an equivalent volume of PBS was  used in place
of  the speciﬁc primary antibodies. The immunostaining tis-
sue  samples were  visualized under a light microscope (Eclipse
E800,  Nikon, Japan) and ﬁve photomicrographs were  taken
from  high power ﬁelds (400× magniﬁcations) randomly. The
average  optical density (AOD) from the photomicrographs was
then  quantitated using the high resolution pathological image
analysis  system (HPIAS-1000; QianPing Corporation, Wuhan,
China)  to measure protein expression levels of Bcl-2, BAX and
Caspase-3.  The ratio of BAX to Bcl-2 was  determined individ-
ually  from each photograph accordingly.
TUNEL  assay
TUNEL (terminal transferase-mediated 20-deoxyuridine 50-
triphosphate-biotin nick end labeling) staining on parafﬁn-
embedded sections was  used to evaluate the effect of IL-28A
on  CVB3-induced apoptosis according to the instructions pro-
vided by the manufacturer. Brieﬂy, 4 m-thick sections were
dewaxed,  rehydrated, and incubated with terminal deoxynu-
cleotidyl  transferase enzyme in a humectous chamber at 37 ◦C
for  1 h. The reaction was  detected by incubation with anti-
digoxigenin-peroxidase for 30 min  in a humidiﬁed chamber
at  room temperature and visualized in a buffer containing
diaminobenzidine. The specimens were counterstained by
immersion  in hematoxylin. The stained tissue samples were
observed  using a ﬂuorescence microscope (Olympus BX 40,
Japan)  and ﬁve photomicrographs were obtained from high
RE
TRpower  ﬁelds (400× magniﬁcations). The cells with apparent
nuclear labeling were  considered TUNEL positive. The percent-
age  of TUNEL-positive cells in the total cell population was
then  quantitated to assess the apoptosis index.25following CVB3 infection (p < 0.001).
Statistical  analysis
Data were  presented as means ± SD. One-way analysis of vari-
ance  (ANOVA) was  used to determine differences between
individual mice for IP scores and myocardial viral titers. The
survival  rate was analyzed by the Kaplan–Meier estimate. All
statistical  analyses were  performed using SPSS 13.0 (SPSS Inc.,
Chicago, IL). Any p-values <0.05 were considered statistically
signiﬁcant.
Results
IL-28A  treatment  protects  mice  from  CVB3
infection-associated  death
Uninfected BALB/c mice appeared healthy whereas CVB3-
inoculated mice displayed signs of serious illness, including
rufﬂed  and dirty fur, soft feces, lethargy, and huddling
behavior. Twelve mice in the infected group died after infec-
tion,  with six, ﬁve and one mice dying on days 6, 9 and
12  post-infection, respectively. However, treatment with IL-
28A  improved mices’ general appearance, and completely
prevented CVB3 infection-associated death up to 14 days post-
infection,  even with the lower dose of IL-28A (10 g/kg). The
Kaplan–Meier analysis clearly showed much  higher survival
rate  in IL-28A treated mice than untreated mice (infected
group) following CVB3 infection (Fig. 1) (p < 0.001).
IL-28A  treatment  inhibits  CVB3  infection-induced
inﬂammation  and  myocardial  lesion
CTHistological examination of the H&E-stained slides showed
evidence  of lymphocyte inﬁltration and myocardial necrosis
on  day 7 after CVB3 infection (Fig. 2A) compared to controls.
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Fig. 2 – IL-28A decreased the IP score of CVB3-infected mice. (A) Uninfected and CVB3-infected mice were  treated with or
without 40 g/kg IL-28A for 4 days. Heart tissue was  removed on day 7 post-infection and subjected to H&E staining (200×
magniﬁcation) to examine myocardial inﬂammation and injury. The arrow indicated a site of lymphocyte inﬁltration in the
heart tissue following CVB3 infection. (B) Uninfected BALB/c mice were  treated with or without 40 g/kg IL-28A.
CVB3-infected mice were  exposed to different doses of IL-28A for 4 days. Heart tissue was  then removed on day 7
post-infection and subjected to H&E staining to quantitate IP scores. Treatment with IL-28A signiﬁcantly reduced the IP
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EDcores in the hearts of IL-28A treated mice compared with in
owever, the severity of cellular inﬁltration was  signiﬁcantly
educed in IL-28A treated group (40 g/kg). As shown in Fig. 2B,
VB3  infection increased the IP score to 2.81 ± 0.22, while in
ninfected  control and IL-28A groups the basal score was  0,
ith  inﬂammation or generalized myocardial ﬁber necrosis
ndetected (N.D.). Despite no effect on uninfected mice, IL-
8A  treatment reduced the IP score of CVB3-infected mice in
 dose-dependent manner (p < 0.01). A dose of 40 g/kg almost
ompletely eliminated cardiac inﬂammatory inﬁltration and
rotected  cardiac myocytes from damage, with the average
P  score on day 7 post-infection being reduced to 0.4 ± 0.1
p  < 0.01) compared with the infected group. Treatment with
 low-dose IL-28A (10 g/kg) also statistically reduced the IP
core  compared with the untreated infected group, but at a
evel  inferior to that with 20 g/kg IL-28A.
L-28A  reduces  cardiac  viral  load
RE
TRnoculation of CVB3 in BALB/c mice resulted in considerably
igh levels of cardiac viral load (6432 ± 291 pfu/mg) detected
y  the plaque assay on day 4 post-infection (Fig. 3A), which
hen  spontaneously declined to 550 ± 50 pfu/mg heart tissueed mice (**p < 0.01).
on  post-infective day 7 (Fig. 3B). As expected, treatment with
IL-28A  dose-dependently reduced cardiac viral load four days
after  CVB3 infections (p < 0.01), even at the low dose (10 g/kg).
On  post-infective day 7, there was a further reduction in car-
diac  viral load in mice treated with IL-28A compared with that
of  untreated infected group (p < 0.01, Fig. 3B).
IL-28A  upregulates  the  expression  of  STAT1  and  STAT2
Treatment with 40 g/kg IL-28A dramatically increased the
protein  levels of STAT1 and STAT2 in the heart tissues of mice 4
days after CVB3 infection (Fig. 4). No signiﬁcant difference was
observed  in the levels of STAT1 and STAT2 between untreated
infected  and control groups.
IL-28A  inhibits  CVB3-induced  apoptosis  of  the  myocardial
cells  in  miceFollowing CVB3 infection, apoptosis was triggered with a sig-
niﬁcant  increase in apoptosis index in the infected mice (0.7%)
compared  to control group (0.1%) (p < 0.01, Fig. 5). However, a
signiﬁcant decrease in apoptotic index was  observed in IL-28A
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Fig. 3 – IL-28A decreased viral load of heart tissue in
CVB3-infected mice. Uninfected and CVB3-infected mice
were  treated with or without IL-28A for 4 days. Heart tissue
of  infected mice were  removed on day 4 (A) and day 7 (B)
post-infection and subjected to plaque assays. Treatment
with  IL-28A signiﬁcantly reduced myocardial viral load
Control
STAT2
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Actin
Treated Infected
Fig. 4 – IL-28A increased the expression of STAT1 and
STAT2  in heart tissue. Uninfected and CVB3-infected mice
were  treated with or without IL-28A (40 g/kg) for 4 days,
then the heart tissues of infected mice were  removed on
day  4 post-infection and subjected to Western blot analysis.
Actin  was  used as a loading control. The amount of STAT2,
STAT1  and Actin was  quantiﬁed using NIH Image J and the
ratio  of STAT2 or STAT1 to Actin was  graphed in the lower
panels.  IL-28A treatment resulted in a signiﬁcant increase
in  the expression of STAT1 and STAT2 compared to infected
A
EDcompared  with infected mice (**p < 0.01).
(0.39%) treated mice compared to the untreated infected group
(p  < 0.01, Fig. 5), suggesting that treatment with IL-28A could
inhibit  CVB3-induced apoptosis in myocardial cells.
As  shown in Fig. 6A, infection with the CVB3 substantially
decreased the expression levels of Bcl-2 and upregulated the
expressions  of BAX and Caspase-3 compared to controls, while
IL-28A  treatment had a reverse effect on the expression levels
of  these apoptosis-related proteins, with increased expression
levels  of Bcl-2 and decreased expression of BAX and Caspase-
3.  The quantitative data further showed that CVB3 infection
induced  a 2-fold down-regulation of Bcl-2 expression, 5-fold
upregulation of BAX expression, as well as a 10-fold decrease
in  the ratio of Bcl-2 to BAX compared with uninfected control
mice  (Fig. 6B and C). Treatment with IL-28A upregulated the
expression  of Bcl-2 by 5-fold, down-regulated the expression
of  BAX by 2.5-fold, and consequently increased the ratio of Bcl-
2 to BAX by 10-fold compared to the untreated group following
CVB3  infection (Fig. 6B and C).
RE
TRDiscussion
It was  demonstrated that CVB3 infection in humans
frequently progresses to cardiomyopathy, left ventriculargroup  (**p < 0.01).
dysfunction, and subsequent chronic heart failure.2 Despite
the  growing knowledge about viral myocarditis, it remained
challenging to manage patients with viral myocarditis due to
lack of effective antiviral therapeutic regimens.26 In this study,
the  results showed that IL-28A protected mice from CVB3-
induced  death, inhibited viral replication in heart tissues
following CVB3 infection, and reduced the induced inﬂamma-
tion  and myocardial lesion.
From  the results, no inﬂammation or generalized myocar-
dial  ﬁber necrosis was  detected (N.D.) in uninfected control
and  IL-28A groups (40 g/kg IL), suggesting that this cytokine
does  not cause apparent side effects in mice. A relatively
low dose (10 g/kg) of IL-28A was  sufﬁcient to reduce CVB3-
induced myocarditis in mice as evidenced by signiﬁcantly
decreasing IP scores and cardiac viral load, let alone treatment
with  40 g/kg IL-28A, which almost completely inhibited car-
diac  inﬂammatory inﬁltration and protected myocytes from
injury  with IP score decreased to 0.4 ± 0.1. It seemed that IL-
28A  was  a highly effective and tolerable antiviral agent against
CVB3-induced myocarditis, although further clinical trials will
be conducted to ensure its effectiveness and safety in human
patients.
Consistent  with previous reports,27 this study also demon-
strated that viral replication was a dominant pathological
process in the early stages of CVB3 infection, as evidenced by
a very high viral load with relatively low levels of inﬂamma-
tory  inﬁltration and tissue injury in the heart on day 4. This
was  followed by a spontaneous reduction of viral load but a
further  development of inﬂammation and injury in cardiac
Ctissue  on day 7, which would deteriorate general health, as
evidenced  by the presence of death on day 6 to 12. The spon-
taneous  decay of viral load might be attributed to an activation
b r a z j i n f e c t d i s . 2 0 1 5;1 9(2):132–140  137
Control Treated Infected
Control Treated Infected
0
0.5
1.0
2.0
1.5
A B C
Ap
op
to
tic
 in
de
x 
(%
)
Fig. 5 – Effect of IL-28A on apoptosis in cardiac myocytes. IL-28A decreased the apoptotic index in heart tissue compared to
the infected group (**p < 0.01). Uninfected and CVB3-infected mice were treated with or without IL-28A (40 g/kg) for 4 days,
then heart tissues of mice were  removed on day 4 post-infection and subjected to TUNEL assay. The stained tissue from
control (A), CVB3-infected (B), and IL-28A-treated mice (C) were  photographed under a ﬂuorescence microscope (400×
magniﬁcation). The cells with apparent nuclear labeling were  considered TUNEL positive. The percentage of TUNEL-positive
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Dells in the total cell population was  then quantitated to ass
f the innate cellular defense mechanisms including the IFN
ystem.28–30 As type III IFNs including IL-28A, IL-28B and IL-
9  are frequently upregulated in response to certain types of
irus  infections and exerted antiviral activity in vitro.15,18,31
his study ﬁrst documented the efﬁcacy of IL-28A in inhibiting
VB3 replication in heart tissues of infected mice. Unlike type I
FNs using IFNAR (composed of subunits IFNAR1 and IFNAR2c)
s  a receptor, type III IFNs signaled through a heterodimeric
eceptor composed of IL-28R (IFN-R1 or CRF2-12) speciﬁc to
FN-,  and IL-10R (IL-10R2 or CRF2-4) shared with all other
L-10-related cytokines.15,31,32 However, upon binding their
peciﬁc cell surface receptors, type I and type III IFNs trigger
he  same Jak-STAT signal transduction pathway,33,34 leading to
he upregulation of many  genes, called IFN-stimulated genes
ISGs).35
Our ﬁndings demonstrated that IL-28A markedly increased
he  expressions of STAT1 and STAT2, indicating that these two
roteins were  the key antiviral regulators in CVB3-infected
eart tissues of mice. It was  well documented that activa-
ion  of STAT1 and STAT2 was  essential for antiviral effect of
FNs.  Following virus nucleic acids recognized by transmem-
RE
TRrane  toll-like receptors (TLRs), cytoplasmic DNA sensors and
NA  helicases, kinases were activated. These kinases would
romote  the activation of transcription factors and their sub-
equent  translocation to the nucleus where they stimulatedhe apoptosis index (D).
IFN  gene transcription. After binding to the cognate recep-
tors,  type I and type III IFNs induced the same Jak/STAT
pathway to activate STAT1 and STAT2 transcription factors.
Then  phosphorylated forms of STAT1 and STAT2 were  further
associated  with the DNA-binding protein IFN regulatory fac-
tor  9 (IRF-9) to form an IFN-stimulated gene factor 3 (ISGF3)
complex,16,35 which was  also a crucial mediator in the type 1
interferon  receptor (IFNAR) signaling pathway.36 Then ISGF3
was  translocated to the nucleus, bound to IFN-stimulated
response elements (ISREs) within the promoters of interferon-
stimulated genes (ISGs) and activated the transcription of
ISGs.16,35 Although the complete signaling cascade initiated by
the  binding of IFN to its receptor had not yet been fully eluci-
dated,  current evidence indicates that the signaling pathways
activated  by IFN-/ and IFN- may  be similar or overlap.14,37
Thus, the ﬁndings about the expressions of STAT1 and STAT2
expression  induced by IL-28A provided a reasonable mecha-
nism  responsible for IL-28A-mediated antiviral effect.
As  apoptosis was implicated in virus-induced myocardial
injury,5,6 the effect of IL-28A on CVB3-induced apoptosis was
also  determined. The results showed that treatment with IL-
28A could inhibit CVB3-induced apoptosis in myocardial cells
as  evidenced by a signiﬁcant decrease in apoptotic index in IL-
28A (0.39%) treated mice compared to the untreated infected
group  (p < 0.01). This could be attributed to the regulating
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Fig. 6 – Immunohistochemistry staining of Bcl-2, BAX and caspase-3. IL-28A enhanced the expression of Bcl-2 (p < 0.01) and
decreased the expression of BAX (p < 0.01) and caspase-3 (p < 0.01) in heart tissue. Uninfected and CVB3-infected mice treated
with or without IL-28A (40 g/kg) for 4 days, then heart tissue of mice were  removed on day 4 post-infection and subjected
to  immunohistochemistry staining. The immunostained tissue samples were  visualized and photographed under a light
microscope (A). A total of ﬁve photomicrographs were  taken from ﬁve high power ﬁelds (400× magniﬁcation) randomly. AOD
from the photomicrographs was then quantitated to measure the protein expression levels of Bcl-2 and BAX (B) as described
in the Section of Materials and Methods. The ratio of BAX to Bcl-2 was  determined individually from each photograph (C).
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Ab r a z j i n f e c t d i s .
ffect of IL-28A on the expression of caspase-3, BAX and Bcl-2,
hich  were  key molecules regulating apoptosis.38–40 The Bcl-2
ould  inhibit apoptosis by binding to BAX while BAX promoted
poptotic  cell death by binding to itself.41 Speciﬁcally, in cells
ith  BAX overexpression, BAX/BAX homodimers predomi-
ated,  and turning the cells susceptible to induced apoptosis.
onversely, in cells with Bcl-2 overexpression, BAX/Bcl-2 het-
rodimers  predominated and the cells became resistant to
poptosis.41 Since BAX, a proapoptotic protein, antagonized
he  function of Bcl-2, it had been generally considered that
he  Bcl-2/BAX ratio could determine the susceptibility of a cell
o apoptotic stimulus.42,43 Besides, caspase-3, a member of
he  cysteine-aspartic acid protease (caspase) family, acted as
he executant of cellular apoptosis.44,45 According to the above
eports,  the result also showed that IL-28A reduced the expres-
ions  of BAX and caspase-3 but upregulated Bcl-2 expression,
hereby resulting in an increase in the Bcl-2/BAX ratio and sub-
equent inhibition of CVB3-induced myocardial cell apoptosis
n  mice. Interestingly, previous studies demonstrated that the
ctivation  of STAT1 not only served to increase the expres-
ion  of Bcl-246 but also negatively regulated BAX expression.47
herefore, it seemed that, in addition to its antiviral effect
s  discussed above, STAT1 activated by IL-28A might bind
o  the promoters of Bcl-2 or BAX, contributing to positive
nd  negative regulation of Bcl-2 and BAX expression, respec-
ively.  Hence, IL-28A might increase the ratio of Bcl-2/BAX and
onsequently  inhibit CVB3 infection-induced apoptosis of the
yocardium  in mice by the above mechanism.
In conclusion, this study demonstrated that IL-28A played
n  important role in the host innate defense against CVB3
nfection  and could inhibit CVB3-induced myocarditis in mice.
he  study also suggested that STAT1 and STAT2 are the key
ntiviral  regulators in heart tissues of CVB3-infected mice,
ith  the former IL-28A could increase the ratio of Bcl-2/BAX
nd  consequently inhibit CVB3 infection-induced apoptosis
f  the myocardium. Thus it could be concluded that IL-28A
ad  a great potential to become a therapeutic intervention for
VB3 infection in humans; however, the precise mechanisms
y  which IL-28A exerted the antiviral defense still need to be
xplored in the future.
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